Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
DATE PUBLISHED: 2022 Aug 26
JOURNAL:J Dermatolog Treat
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36026543?dopt=Abstract
To describe real-world baseline characteristics and patient-reported outcomes (PROs) at 6- and 12-month follow-up visits among patients with psoriasis who initiated and maintained secukinumab, stratified by prior exposure to biologics.
